Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | F13A1 | P00488 | 1/20 | 0.34 |
| ▸ | TGM2 | P21980 | 1/20 | 0.34 |
| ▸ | TGM1 | P22735 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1267927 | 1.00 | CYP1A2 (0.42) | CYP1A2POLBCYP3A4CYP2C19CHRM2 | |
| SCHEMBL1268152 | 1.00 | CYP1A2 (0.42) | CYP1A2POLBCYP3A4CYP2C19CHRM2 | |
| SCHEMBL178642 | 1.00 | CYP1A2 (0.42) | CYP1A2POLBCYP3A4CYP2C19CHRM2 | |
| SCHEMBL12836636 | 1.00 | CYP1A2 (0.42) | CYP1A2POLBCYP3A4CYP2C19CHRM2 | |
| SCHEMBL1267911 | 0.87 | NR1H2 (0.38) | CYP1A2POLBCYP3A4CYP2C19CHRM2 | |
| SCHEMBL1268168 | 0.87 | NR1H2 (0.38) | CYP1A2POLBCYP3A4CYP2C19CHRM2 | |
| SCHEMBL3964957 | 0.87 | NR1H2 (0.38) | CYP1A2POLBCYP3A4CYP2C19CHRM2 | |
| SCHEMBL15909556 | 0.82 | NR1H2 (0.49) | CYP1A2POLBCYP3A4CYP2C19CHRM2 | |
| SCHEMBL1722772 | 0.82 | CYP1A2 (0.45) | CYP1A2POLBCYP3A4CYP2C19CHRM2 | |
| SCHEMBL20371652 | 0.82 | CYP1A2 (0.45) | CYP1A2POLBCYP3A4CYP2C19CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008007930-A9 | MELANOCORTIN RECEPTOR AGONISTS | LG LIFE SCIENCES LTD (KR) | 2009-04-02 | — | — | WO | disclosed |
| EP-2041120-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG Life Sciences Ltd. (KR) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008007930-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2008-01-17 | — | — | WO | disclosed |
| US-7132539-B2 | Melanocortin receptor ligands | THE PROCTER & GAMBLE COMPANY (US) | 2006-11-07 | — | — | US | disclosed |
| US-20060247224-A1 | Melanocortin receptor ligands | THE PROCTER & GAMBLE COMPANY | 2006-11-02 | — | — | US | disclosed |
| US-7087759-B2 | for controlling weight; pyrrolidine or piperidine compounds | THE PROCTER & GAMBLE COMPANY (US) | 2006-08-08 | — | — | US | disclosed |
| US-20060106059-A1 | Melanocortin receptor ligands | MAZUR WIESLAW A | 2006-05-18 | — | — | US | disclosed |
| EP-1390361-A4 | MELANOCORTIN RECEPTOR LIGANDS | PROCTER & GAMBLE (US) | 2005-10-05 | — | — | EP | disclosed |
| EP-1556361-A2 | 2-ALKYL-(2-AMINO-3-ARYL-PROPIONYL)-PIPERAZINE DERIVATIVES AND RELATED COMPOUNDS AS MELANOCORTIN RECEPTOR LIGANDS FOR THE TREATMENT OF OBESITY | THE PROCTER & GAMBLE COMPANY (US) | 2005-07-27 | — | — | EP | disclosed |
| US-6911447-B2 | Melanocortin receptor ligands | THE PROCTER & GAMBLE COMPANY (US) | 2005-06-28 | — | — | US | disclosed |
| US-20050010031-A1 | Melanocortin receptor ligands | THE PROCTER & GAMBLE COMPANY | 2005-01-13 | — | — | US | disclosed |
| US-20040224985-A1 | Melanocortin receptor ligands | THE PROCTER & GAMBLE COMPANY | 2004-11-11 | — | — | US | disclosed |
| WO-2004037797-A2 | 2 - ALKYL - (2 - AMINO - 3 - ARYL - PROPIONYL) - PIPERAZINE DERIVATIVES AND RELATED COMPOUNDS AS MELANOCORTIN RECEPTOR LIGANDS FOR THE TREATMENT OF OBESITY | THE PROCTER & GAMBLE COMPANY (US) | 2004-05-06 | — | — | WO | disclosed |
| EP-1390361-A2 | MELANOCORTIN RECEPTOR LIGANDS | THE PROCTER & GAMBLE COMPANY (US) | 2004-02-25 | — | — | EP | disclosed |
| US-20030109556-A1 | Melanocortin receptor ligands | THE PROCTER & GAMBLE COMPANY | 2003-06-12 | — | — | US | disclosed |
| WO-2002085925-A2 | MELANOCORTIN RECEPTOR LIGANDS | THE PROCTER & GAMBLE COMPANY (US) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050010031-A1 | Melanocortin receptor ligands | MC3R, MC5R, MC1R | CYP1A2 1718/4885POLB 4303/4885CYP3A4 2803/4885 |
| US-20030109556-A1 | Melanocortin receptor ligands | MC3R, MC4R, MC1R | CYP1A2 1953/4885POLB 4436/4885CYP3A4 850/4885 |
| US-20060106059-A1 | Melanocortin receptor ligands | MC3R, MC4R, MC1R | CYP1A2 2334/4885POLB 4298/4885CYP3A4 1057/4885 |
| US-20040224985-A1 | Melanocortin receptor ligands | MC3R, MC4R, MC1R | CYP1A2 1953/4885POLB 4436/4885CYP3A4 850/4885 |
| US-20060247224-A1 | Melanocortin receptor ligands | MC3R, MC5R, MC1R | CYP1A2 1310/4885POLB 4170/4885CYP3A4 2571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.